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ABSTRACT
Background Craniosynostosis can be caused by both
genetic and environmental factors, the relative
contributions of which vary between patients. Genetic
testing identiﬁes a pathogenic mutation or chromosomal
abnormality in w21% of cases, but it is likely that further
causative mutations remain to be discovered.
Objective To identify a shared signature of genetically
determined craniosynostosis by comparing the
expression patterns in three monogenic syndromes with
a control group of patients with non-syndromic sagittal
synostosis.
Methods Fibroblasts from 10 individuals each with
Apert syndrome (FGFR2 substitution S252W), Muenke
syndrome (FGFR3 substitution P250R), SaethreeChotzen
syndrome (various mutations in TWIST1) and non-
syndromic sagittal synostosis (no mutation detected)
were cultured. The relative expression of w47000
transcripts was quantiﬁed on Affymetrix arrays.
Results 435, 45 and 46 transcripts were identiﬁed in the
Apert, Muenke and SaethreeChotzen groups,
respectively, that differed signiﬁcantly from the controls.
Forty-six of these transcripts were shared between two
or more syndromes and, in all but one instance, showed
the same direction of altered expression level compared
with controls. Pathway analysis showed over-
representation of the shared transcripts in core modules
involving cell-to-cell communication and signal
transduction. Individual samples from the Apert
syndrome cases could be reliably distinguished from non-
syndromic samples based on the gene expression proﬁle,
but this was not possible for samples from patients with
Muenke and SaethreeChotzen syndromes.
Conclusions Common modules of altered gene
expression shared by genetically distinct forms of
craniosynostosis were identiﬁed. Although the
expression proﬁles cannot currently be used to classify
individual patients, this may be overcome by using more
sensitive assays and sampling additional tissues.
Craniosynostosis (CRS), the premature fusion of
one or more of the cranial sutures, affects 1 in every
2100e2500 children and requires multidisciplinary
management to address potential complications,
which include raised intracranial pressure, problems
with vision, hearing, breathing and feeding,
learning difﬁculties, and signiﬁcant cosmetic
deformity.
1
CRS is very heterogeneous, in both presentation
and aetiology. Patients may variously be classiﬁed
according to which sutures are fused, the associa-
tion with identiﬁed genetic or environmental risk
factors, the presence of additional clinical features
suggestive of a syndrome, or the identiﬁcation of
a causative genetic mutation or chromosomal
abnormality. About two-thirds of patients have
non-syndromic synostosis affecting a single suture,
the sagittal suture being most commonly involved
(accounting for up to 50% of all individuals with
CRS).
1 Non-syndromic sagittal synostosis (NSS)
occurs in males about four times as often as in
females, but no other genetic risk factors have been
consistently demonstrated, and epidemiological
evidence indicates that the genetic contribution to
this disorder is largely polygenic.
2e4 Although
intrauterine fetal head constraint is suspected to
represent an important risk factor for sagittal
synostosis,
35it is challenging to prove this in
individual cases because objective data on fetal head
constraint are difﬁcult to obtain.
At the other end of the spectrum of causation,
a speciﬁc genetic aetiology (either single gene
mutation or chromosome abnormality) can be
identiﬁed in w21% of patients, the majority of
whom have additional clinical features indicating
the presence of a syndrome.
6 Heterozygous muta-
tions in the ﬁbroblast growth factor receptor type 2
(FGFR2) and type 3 (FGFR3) genes, and the
TWIST1 gene, are most commonly identiﬁed.
7 The
FGFR2 and FGFR3 mutations usually encode
speciﬁc missense substitutions that confer gain-
of-function to the mutant receptor tyrosine kinase,
whereas the TWIST1 mutations are heterogeneous
and result in loss-of-function (haploinsufﬁciency)
of the encoded basic helixeloopehelix transcrip-
tion factor. The most common individual CRS-
related substitutions are S252W and P253R
in FGFR2 (causing Apert syndrome; AS) and P250R
in FGFR3 (causing Muenke syndrome; MS)
68 ;
TWIST1 mutations are diagnostic of Saethree
Chotzen syndrome (SCS).
9
Genetic counselling for families affected with
CRS is straightforward when the proband has
either non-syndromic midline suture synostosis
(risks are relatively low and empiric data can be
used) or an identiﬁed genetic alteration (genetic
testing identiﬁes those individuals at risk).
However, it is much more challenging in the
minority of cases (w15e20%)
6 in whom either
a syndrome is suspected (based on positive family
history, additional dysmorphic features or learning
disability), or multiple cranial sutures are fused, but
where all currently available genetic tests are
negative. This situation is clearly unsatisfactory as
the various aetiological possibilities in this situation
(dominant, recessive, polygenic) are associated with
very different recurrence risks.
To provide an alternative approach to the inves-
tigation of causation, we sought here to identify
a characteristic signature, based on ﬁnding altered
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Original articlepatterns of mRNA expression in ﬁbroblasts, that could poten-
tially provide a biological marker of genetically mediated CRS.
We chose to analyse ﬁbroblasts for two reasons. Firstly, these can
readily be cultured at the time of craniofacial surgery from
a small biopsy sample of scalp skin, enabling the standardisation
of the sampling protocol and greater simplicity for diagnostic
purposes. Secondly, ﬁbroblasts are developmentally related to
osteoblasts, which have been described as ‘sophisticated ﬁbro-
blasts’,
10 and therefore represent a particularly relevant cell type
in the context of CRS. By comparing the expression patterns in
three of the most common genetic types of CRS with NSS cases,
we have identiﬁed shared modules of altered gene expression in
the syndromic groups that indicate a common pathogenetic
pathway involving cell-to-cell communication and signal
transduction. These results provide a starting point for a new
functional method of classifying CRS based on the mRNA
expression proﬁle.
SUBJECTS AND METHODS
Patients and samples
Ethics approval for the work was obtained from the Oxfordshire
Research Ethics Committee (C02.143). Patients with suspected
diagnoses of AS, MS and SCS were screened for mutations in
FGFR2, FGFR3 and TWIST1, respectively, by restriction digest,
denaturing high-performance liquid chromatography (Trans-
genomic WAVE System) and DNA sequencing of appropriate
PCR products.
8 Patients with TWIST1 mutations from whom
we obtained samples were all reported on previously.
11 Patients
with NSS were screened for all common mutations in FGFR1,
FGFR2, FGFR3 and TWIST1.
6 At operation, a transverse incision
was made across the vertex of the scalp, and a strip of skin
(w2c m 30.3 cm) was removed from the incision site before
closure. In two cases of AS, skin was taken from the hand at the
time of a corrective procedure. Online supplementary table 1
summarises the mutational data, site of tissue sampling, and age
of the patient when each sample was obtained. For the micro-
array studies, the average age at sampling ranged from 1.40 years
for the NSS group to 3.96 years for the MS group, the difference
in age was not statistically signiﬁcant for any of the groups
(t test).
Skin was cultured at 378C with 5% CO2 in Dulbecco’s
modiﬁed Eagle’s medium (Invitrogen, Paisley, UK) supplemented
with 10% fetal calf serum (FCS; catalogue Nos A15-041 and
A15-043, PAA Laboratories GmbH, Pasching, Austria) and frozen
in 50% FCS for storage. Frozen cells were thawed and grown to
w70% conﬂuency in a 75 cm
3 ﬂask before RNA extraction. All
analyses were conducted on cells passaged between three and
ﬁve times.
RNA extraction and microarray processing
Total RNA was extracted using TRIzol (Invitrogen) following
the manufacturer’s protocol. The quality of RNA samples was
evaluated using the Agilent Bioanalyzer 2100 (Agilent Techno-
logies, South Queensferry, UK). Only samples with preserved
rRNA ratio (28S/18S) and no evidence for RNA degradation
were analysed further.
RNA labelling and hybridisation used protocols, reagents and
equipment supplied by Affymetrix, High Wycombe, UK. A 2 mg
portion of total RNA from each sample was labelled with the
One-Cycle cDNA Synthesis and One-Cycle Target Labelling and
Control Reagent kits. Then 10 mg of the resulting biotin-labelled
fragmented cRNA was hybridised to GeneChip Human Genome
U133 Plus 2.0 arrays, which identify over 47000 transcripts.
After hybridisation at 458C for 16 h (Hybridisation Oven 640),
microarrays were washed and stained with streptavidine
phycoerythrin conjugate in a Fluidics Station 450, and scanned
with a GeneChip Scanner 3000.
Microarray data analysis
After array scanning, quality control (QC) was performed with
GCOS software (Affymetrix). All QC measures (scaling factor
#3-fold difference within a study; 39/59 ratio for probe sets for
GAPDH #3; present (P) calls in the same range for all samples in
the study and RawQ below 100) were in the acceptable range for
all samples. The .CEL data ﬁles have been deposited in
ArrayExpress (accession No E-MEXP-2236).
Affymetrix GeneChip .CEL ﬁles were analysed in R (see
http://www.r-project.org) using the Bioconductor packages
(http://www.bioconductor.org) for QC analysis, data normal-
isation, hierarchical clustering, and identiﬁcation of differentially
expressed transcripts. Speciﬁcally, the data were normalised
using Robust MultiChip Analysis,
12 and differentially expressed
genes were identiﬁed using Statistical Analysis for Microarrays
(SAM) with a false discovery rate cut-off of 5%.
13 Prediction
Analysis for Microarrays (PAM) was implemented to determine
if a gene set could be identiﬁed that classiﬁed the arrays correctly
when cross-validation was applied.
14 Both unsupervised and
supervised two-way (genes against samples) hierarchical clus-
tering methods were used to establish the relationships among
samples and to check if the individual samples clustered together
according to similarity in their expression signatures. Hierar-
chical clustering was performed with Genesis software using
complete linkage clustering.
15
Gene lists produced using the above methods were subse-
quently imported into Ingenuity and mined by Ingenuity
Pathways Analysis (IPA) (Ingenuity Systems, US; http://www.
ingenuity.com). This core gene list was analysed for gene
annotation enrichment using the Database for Annotation,
Visualisation and Integrated Discovery (DAVID) 2008; the
enriched functional annotation terms associated with each gene
were identiﬁed and listed according to their enrichment p value
(http://niaid.abcc.ncifcrf.gov/).
16 17
Quantitative real-time PCR
To validate the gene expression measurements independently,
we performed quantitative reverse transcription PCR (RT-PCR)
on three genes (HLA-DPA1, MMP1 and TGFBR2) using prede-
signed ABI Taqman primers, probes and ampliﬁcation reagents
(Assays-on-Demand; Applied Biosystems, Warrington, UK),
according to the manufacturer’s instructions. Firstly, 2 mg total
RNA from each subject was reverse-transcribed with the
RETROscript kit (Ambion, Warrington, UK), and the cDNAwas
ampliﬁed by quantitative real-time PCR in an ABI 7500 PCR
system (Applied Biosystems). Ampliﬁcation of the GAPDH gene
served as a normalisation control for each sample to correct for
minor differences in RNA quality and quantity. The expression
ratio was calculated using the 2
 DDCT method.
18 t Tests were
performed to determine signiﬁcant differences in gene expres-
sion, and Fisher exact tests to compare data in 232 tables.
RESULTS
Expression proﬁling of syndromic CRS
Weestablishedprimaryskinﬁbroblastcelllinesderivedfromscalp
skin, from subjects with conﬁrmed diagnoses of AS, MS and SCS,
and control subjects with NSS. Ten samples from each diagnostic
category were chosen for investigation by expression proﬁling
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hybridised to Affymetrix GeneChip U133 Plus 2.0 microarrays,
which comprehensively cover the human transcriptome.
For the ﬁrst stage of the analysis, we asked whether the
samples could be clustered by disease category. Unsupervised
clustering of all samples, based on all transcripts on the micro-
array, produced the dendrogram shown in ﬁgure 1. Eight of 10
AS samples located to a cluster that did not contain any NSS
controls (p¼0.0007), indicating that AS has the most distinctive
expression proﬁle among the four patient groups studied. By
contrast, the MS and SCS samples clustered poorly, and only
a minority (four MS, three SCS) were clearly discriminated from
the NSS controls.
To identify the transcripts that best discriminated the
syndromic patients as a whole from the NSS controls, we used
SAM analysis. A total of 1044 independent probe sets, repre-
senting 863 different genes, were found to be signiﬁcantly
differentially expressed (online supplementary table 2). Of the
141 genes represented by two or more probe sets, the direction of
change in transcription was concordant for the different probe
sets in 139 cases, indicating that the great majority of changes
observed are real rather than the result of statistical noise.
However, supervised clustering using this gene set provided only
modest improvement over unsupervised analysis, with nine of 10
AS samples clustered in a single group that contained one MS
sampleinaddition,butnomajorchangeintheclusteringofMSor
SCS samples (online supplementary ﬁgure 1).
One factor that might have impeded clustering of syndromic
cases from NSS controls is that the different syndromic diag-
noses were associated with different expression signatures. We
therefore repeated the SAM analysis, comparing each syndromic
group (AS, MS, SCS) individually with the NSS controls. This
analysis identiﬁed 547 (AS), 52 (MS) and 56 (SCS) independent
probe sets, representing, respectively, 435 (AS), 45 (MS) and 46
(SCS) differentially expressed genes between the syndromic
cases and the NSS controls (online supplementary table 3). In
the previous SAM analysis of all syndromic versus NSS controls,
163 of the unique gene entries were also represented. The much
larger number of probe sets identiﬁed for the AS ﬁbroblasts
presumably reﬂects a more widespread disturbance in cellular
homoeostasis, and correlates with the greater phenotypic
severity of AS, with regard to both CRS and other skeletal
features, compared with either MS or SCS.
Discrimination of individual syndromic samples from controls
As an alternative approach to testing the use of these data for
sample classiﬁcation, we used PAM analysis for each of the
syndromes compared with controls. In the case of AS, satisfac-
tory discrimination from NSS controls (misclassiﬁcation error
#0.1) could be achieved by the measurement of 91 transcripts
representing 73 genes (ﬁgure 2A). Figure 2B shows the heat map
obtained when clustering using these genes. However, similar
PAM analyses of MS and SCS gave unacceptably high misclas-
siﬁcation error (>0.2) and hence poor classiﬁcation potential
(online supplementary ﬁgure 2).
These results indicate that, while our analytical procedure was
able to distinguish individual AS from NSS samples with good
conﬁdence, it was not reliable in the case of individual MS or
SCS samples.
Identiﬁcation of a common CRS syndromic expression proﬁle
We next asked whether the lists of unique transcripts genera-
ted using the separate SAM analyses of each syndrome
compared with NSS controls, described above (online supple-
mentary table 3), showed signiﬁcant overlap. Of a total of 477
transcripts in these lists, 43 featured in two of the lists and three
in all three lists (ﬁgure 3). All except one of these 46 multiply
listed transcripts showed the same direction of change in the
different syndromic CRS disorders relative to the NSS group,
indicating that these trends were highly non-random (p¼10
 7).
We randomly selected three transcripts signiﬁcantly altered at
least in the AS group for independent assessment by real-time
RT-PCR; the genes chosen were HLA-DPA1 (major histocom-
patibility complex, class II, DP a 1), MMP1 (matrix metal-
lopeptidase 1, interstitial collagenase; also signiﬁcantly altered in
SCS) and TGFBR2 (transforming growth factor beta receptor II
(70/80 kDa); also signiﬁcantly altered in SCS). We analysed both
the original samples used in the Affymetrix microarray experi-
ment (not shown), anddfor further validation on an indepen-
dent set of samplesdﬁve different AS patients with P253R
FGFR2 mutations and ﬁve further NSS controls (ﬁgure 4). In all
cases, the results conﬁrmed the trends originally identiﬁed in the
microarray analysis, indicating that they were independent of
changes in the sample, time of culture, and method of mRNA
quantiﬁcation.
To assess whether particular regulatory networks were
enriched in the lists of discriminating transcripts for the three
Figure 1 Cluster analysis of gene
expression in craniosynostosis (CRS).
The dendrogram shows the results of
unsupervised clustering analysis of 10
samples each of Apert syndrome (AS)
(AP_01eAP_10), Muenke syndrome
(MS) (M_01eM_10),
SaethreeChotzen syndrome (SCS)
(SCS_01eSCS_10), and 10 non-
syndromic sagittal synostosis (NSS)
controls (C_01eC_10), using
information from all the probe sets of
the Affymetrix U133 Plus 2.0 arrays.
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46 transcripts that had shown differential changes in more than
one CRS syndrome compared with NSS controls (ﬁgure 3) as
belonging to core conserved networks. ‘Network’ genes that
showed increased expression in syndromic CRS are ASS1, IL15,
ITGA11, PDLIM1, SHROOM3, STMN2 and TPD52L1, and those
that showed decreased expression are CA12, DCBLD2, DDX17,
DOCK2, HMGA2, ITGA2, ITGA6, MMP1, MT1E, NPR3,
PHLDA1, PODXL, RAPGEF2, SPRY2 and THBD. This core list
was analysed for gene annotation enrichment using the DAVID
algorithm. Highly signiﬁcant enrichment was identiﬁed for
encoded proteins involved in cell-to-cell communication and
signal transduction (DCBLD2, IL15, ITGA2, ITGA6, ITGA11,
NPR3, RAPGEF2, SPRY2, STMN2) (p¼0.036), with nine of the
proteins integral to the plasma membrane (DCBLD2, IL15,
ITGA2, ITGA6, ITGA11, PODXL, RAPGEF2, SHROOM3,
THBD) (p¼0.0032).
DISCUSSION
In this work we have identiﬁed a shared alteration in expression
proﬁle in scalp ﬁbroblasts obtained from patients with muta-
tions in the three genes that are most commonly mutated in
CRSdFGFR2, FGFR3 and TWIST1. We would expect this proﬁle
to indicate common perturbations in gene networks down-
stream of the mutations, providing insights into the shared
pathogenesis of genetically determined CRS (as opposed to NSS,
which in most cases has a different, multifactorial origin).
Figure 2 Fibroblast expression signature distinguishes Apert syndrome (AS) samples from non-syndromic sagittal synostosis (NSS) controls.
(A) Prediction Analysis for Microarrays (PAM) analysis. The upper panel shows the predictive power (measured by misclassiﬁcation error on the y
axis) of the full list of genes (extreme left on the x axis) to a single classifying gene (extreme right of the x axis). The best predictive power, hence
smallest misclassiﬁcation error, is achieved with the top 73 classifying genes (arrow). The lower panel shows the misclassiﬁcation error for each
diagnosis, with the NSS controls in red and AS cases in green. (B) Supervised clustering and heat map generated with the top 73 AS-classifying genes.
Figure 3 Comparison of syndromic craniosynostosis
(CRS) expression proﬁles. A Venn diagram of the lists
from the Statistical Analysis for Microarrays (SAM)
analysis corresponding to the three conditions (Apert
syndrome (AS), Muenke syndrome (MS) and
SaethreeChotzen syndrome (SCS)) is shown. Genes
showing signiﬁcant alterations in two or more conditions
are identiﬁed individually; upregulated genes are shown
in bold, and downregulated genes in normal type.
A single gene (PDE4DIP, underlined) showed an
inconsistent direction of change, with upregulation in
MS and downregulation in AS.
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connectedness of FGFR2, FGFR3 and TWIST1 in signal trans-
duction events, with similar downstream consequences for
cellular phenotype. In the mouse, all three orthologous genes are
expressed in different zones of the deﬁnitive coronal suture at
embryonic day (E)16.
19 Twist1 appears to have an earlier role at
E14.5 in maintaining the boundary between neural crest and
cephalic mesoderm at the site of the developing coronal suture,
20
whereas Fgfr2 expression is characteristic of actively dividing
cells in the deﬁnitive suture.
21 The presence of TWIST1 binding
sites adjacent to the FGFR2 gene indicates direct transcriptional
regulation
22; in addition, the sutural mesenchyme of Twist1
+/ 
mice shows greater responsiveness to ﬁbroblast growth factors
(FGFs).
23 The role of FGFR3 in the cranial sutures is less well
deﬁned, but it has been proposed that TWIST1 negatively
regulates FGFR3 transcriptional activation induced by its
binding partner E2A.
24
When considering the genes showing altered expression in
more than one CRS syndrome compared with NSS controls
(ﬁgure 3), we found highly signiﬁcant trends both in sharing of
the direction of altered expression and in the classes of encoded
protein affected by these alterations. Together with the repli-
cation, using real-time PCR (RT-PCR), of selected expression
alterations in samples from ﬁbroblasts of a different set of
patients and cultured at a different time (ﬁgure 4), this indicates
that our ﬁndings are robust and point to important biological
differences between the ﬁbroblasts of patients with deﬁned CRS
syndromes and those with NSS. Of note, it is essential to use
a consistent source of FCS during ﬁbroblast culture; in contrast
with the data presented here, when we grew ﬁbroblasts in serum
sourced from a different manufacturer, expression proﬁles on
microarray analysis appeared dampened, and we observed few
signiﬁcant differences even between the AS sample group and
NSS controls (data not shown).
Assessment of the genes showing shared alterations in
expression using a combination of IPA and DAVID classiﬁcation
indicates that ﬁbroblasts from the syndromic patients have
altered characteristics for cell recognition and signalling. Among
genes exhibiting increased expression in syndromic CRS (online
supplementary tables 2 and 3), several encode proteins with
cytoarchitectural functions. Prominent examples are STMN2
(encoding stathmin-like 2), which showed the highest upregu-
lation of any transcript in both MS and SCS (average of 8.7-fold
and 12.0-fold increase respectively), as well as the highest
upregulation overall, and SHROOM3 (encoding shroom family
member 3), which was upregulated 3.07/3.93-fold in AS and
3.48/4.03-fold in MS. Stathmin-like 2 is a cytosolic phospho-
protein that controls microtubule assembly and dynamics, and
is a marker of osteogenesis in mesenchymal stem cells
25; shroom
3 is an actin-binding protein that regulates the apical constric-
tion of epithelial cells.
26 Genes inﬂuencing cell adhesion and
extracellular matrix are also prominent. ITGA11, upregulated
3.78-fold in SCS and 2.38/3.37-fold in AS, encodes half of
a heterodimeric integrin (a11b1) that functions as a collagen
receptor
27; by contrast, genes encoding two other integrin
subunits, ITGA2 and ITGA6, as well as MMP1 (encoding matrix
metalloproteinase 1 (an interstitial collagenase)), were down-
regulated in the same two disorders. SPP1 encoding osteopontin,
the principal phosphorylated glycoprotein of bone, was down-
regulated fourfold in AS and 3.1-fold in MS, and SPRY2,
encoding sprouty 2, a negative regulator of FGF signalling, was
downregulated 2.0-fold in MS and 2.9-fold in SCS.
Whereas these data point to a major inﬂuence of CRS muta-
tions on downstream gene expression, the SAM analysis did not
highlight any signiﬁcant changes in expression of the mutated
genes themselves (TWIST1, FGFR2 or FGFR3) in these samples.
In the PAM analysis, however, two FGFR2 probe sets were
selected among the 73 genes giving the best discrimination of AS
from NSS controls (ﬁgure 1). Interestingly, FGFR2 showed
relative upregulation in AS cells, which contrasts with previous
reports that FGFR2/Fgfr2 expression is either unchanged or
reduced in the cranial sutures of AS individuals or mouse
models.
28e31 Clearly ﬁbroblast culture represents a different
cellular milieu from the cranial suture, and we do not expect
a simple equivalence of gene expression proﬁles between the two
situations. Nevertheless, it is likely that the altered cellular
properties of ﬁbroblasts reﬂect endogenous properties of the
suture, hence the genes that show altered expression are plau-
sible candidates in which mutations may cause CRS. Supporting
this, heterozygous mutations in TGBFR2, which showed
reduced expression in AS (2.17e2.94-fold; ﬁgure 4) and MS
(2.08-fold), cause LoeyseDietz syndrome, in which CRS some-
times occurs.
32
Previously, three other studies have proﬁled gene expression in
CRSusingmicroarrayanalysis oftranscripts.
31 33 34Thesestudies
investigated different cell types compared with the present work
and used diverse array platforms. Carinci et al
33 studied periosteal
ﬁbroblasts of three patients (AS with FGFR2 P253R mutation,
Crouzon syndrome with FGFR2 G338R mutation, and Crouzon
syndrome without an identiﬁed mutation), using a 19K cDNA
array platform. Fanganiello et al
34 studied periosteal ﬁbroblasts in
seven AS patients with the FGFR2 S252W mutation, using the
CodeLink array platform. Coussens et al
31 used tissue samples
from a combination of fused, fusing and unfused sutures in ﬁve
patients (AS with S252W mutation, and three sagittal and one
unicoronal synostosis without identiﬁed mutations), using the
same Affymetrix platform as in the present work. By contrast,
we chose to undertake expression proﬁling in ﬁbroblasts (see the
Introduction); the relative simplicity of harvesting and culture
enabled us to sample a much larger number of patients than
described in the previous studies.
We compared the gene lists generated from the two larger
previously published studies (262 genes in Fanganiello et al
34 and
651 in Coussens et al
31) with our list of 863 differentially
expressed genes between monogenic CRS and NSS controls
(online supplementary table 2). No genes were found in
common to all of the lists, and the overlap of genes shared by
Figure 4 Real-time PCR (RT-PCR) validation of the expression of HLA-
DPA1, MMP1 and TGFBR2 genes in ﬁve further AS cases (P253R
mutation) and ﬁve further NSS controls. The values presented are log-
transformed and normalised to GAPDH control gene expression. All the
data reached statistical signiﬁcance (Student t test, p<0.05).
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none of the three comparisons did the shared transcripts show
changes in a consistent direction for syndromic cases or fusing
sutures more often than expected by chance. Hence we conclude
that, presumably owing to substantial differences in sample
sources and methodology, it is not appropriate to combine the
results of any of these studies. Notably, our experimental design
used ﬁbroblasts from patients with NSS as the ‘control’
comparator group; we did not explore whether these NSS
samples might themselves show consistent differences from
a non-CRS population. Such an effect could have obscured some
of the features of the monogenic CRS expression proﬁle
compared with the normal state.
In summary, we have identiﬁed an expression proﬁle of
syndromic CRS in scalp ﬁbroblasts that exhibits shared features
across three of the most common genetically determined
syndromes (AS, MS, SCS) that distinguish these samples from
NSS controls. As well as demonstrating shared signalling
modules in these three syndromes, this observation supports our
original reasoning that NSS has a distinct pathological origin.
The syndromic CRS proﬁle is robust, based on the consistent
direction of change in expression, and replication in independent
samples. Although, with the exception of AS, this proﬁle cannot
currently distinguish individual samples from NSS, improved
sensitivity of the cDNA assay (for example, using deep
sequencing methods) should increase signal speciﬁcity. Further
reﬁnements to this approach may provide a method of classi-
fying individual samples into dichotomous groups with either
high or low genetic load, which would assist genetic counselling
even when a causative mutation has not been found.
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